Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech: Biotech
Get the latest updates from FierceBiotech: Biotech directly as they happen.
Follow now 89 followers
Latest posts
Last updated about 15 hours ago
Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug
about 15 hours ago
Pathos AI has secured $365 million in series D funds as the...
VC firm reveals plan for 30K-square-foot biotech incubator space in New Jersey
about 16 hours ago
The Garden State is looking to grow into the next big biotech...
Kinase inhibitor biotech Enliven calls time on ph. 1 HER2 solid tumor program
about 18 hours ago
Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug...
FDA delays decision on Biohaven's rare disease drug filing, plans adcomm
about 18 hours ago
Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was...
RA Capital’s biotech incubator lays off staffers: Stat
1 day ago
After RA Capital asked its companies to reassess operations, Raven cut an...
ADC Therapeutics drops only clinical-stage drug after reviewing phase 1 leukemia data
1 day ago
Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time...
AbbVie pays ADARx $335M cash for next-gen siRNA options
1 day ago
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on...
Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates
1 day ago
Allogene Therapeutics is cutting back to stretch its cash runway into the...
Alumis' Acelyrin merger back on track after shareholders unswayed by activist investor
1 day ago
Acelyrin’s shareholders have decided to power ahead with a planned merger with...
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
2 days ago
Novo Nordisk is making yet another bet on obesity, offering Septerna more...
Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace
2 days ago
Kyverna Therapeutics may consider it had an “exceptional start to the year,”...
GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead liver disease drug
2 days ago
GSK is brushing off dropping a cancer asset on Tuesday by snagging...